Heterozygous ITGA2B Phe1024 Deletion Associated with Abnormal αIIbβ3 Function in a Patient with Congenital Thrombocytopenia
Bin Wang,Ning Tang,Hongyan Hou,Junkun Chen,Xiong Wang,Jiaoyuan Li
DOI: https://doi.org/10.1055/s-0044-1785655
2024-04-12
Seminars in Thrombosis and Hemostasis
Abstract:Integrin αIIbβ3 (previously called glycoprotein [GP] IIb/IIIa) is a transmembrane GP receptor, which plays a crucial role in blood coagulation by mediating platelet aggregation.[1] [2] After activation, this receptor initiates platelet aggregation rapidly through changing its conformation and introducing the interaction of platelets with a wide array of ligands such as fibrinogen, fibronectin, and von Willebrand factor (VWF). Germline mutations in genes encoding the subunits of the complex, integrin subunit α 2b ( ITGA2B ) and integrin subunit β 3 ( ITGB3 ), have been reported mainly in the platelet-type bleeding disorder Glanzmann thrombasthenia (GT).[3] GT is a congenital disease that follows an autosomal recessive inheritance pattern and exhibits failure or deficiency of platelet aggregation, although with normal platelet counts and morphology.[4] However, several αIIbβ3 variants have also been identified in patients with congenital macrothrombocytopenia, a genetically heterogeneous group of rare disorders characterized by abnormal giant platelets, reduction of platelets, and bleeding tendency with variable severity.[5] Our case is a 13-year-old boy who was referred to our hospital because of hemostatic difficulty after a first episode of epistaxis. His platelet count was 79 × 10 9 /L (normal range: 150–407 × 10 9 /L); the mean platelet volume (MPV) and platelet distribution width (PDW) were close to the upper limit of the reference intervals (MPV: 13.7fL, normal range: 9.0–13.8 fL, PDW: 21.5 fL, normal range: 9.8–21.9 fL). Six months later, the patient was referred to our hospital again due to sporadic petechia of skin. At that time, routine blood test of the patient showed mild reduction in platelet count (102 × 10 9 /L), with no abnormalities of MPV (12.9 fL) and PDW (18.6 fL). His blood cell smear identified a few giant platelets (4 in a standard automated smear in Mindray blood analyzer MC-80), while without obvious reduction of cytoplasmic granules ([Fig. 1A] and [B]). Except for a slight rise near the upper boundary of activated partial thromboplastin time (37.0 seconds; normal range: 25.1–36.5 seconds), other coagulation indicators, including prothrombin time (PT), prothrombin activity, fibrinogen, thrombin time (TT), and international normalized ratio, were all within normal ranges. VWF level and activity were also within normal limits. Platelet aggregation induced by adenosine diphosphate (ADP), collagen, adrenalin, or arachidonate were each substantially reduced ([Fig. 2A]), to varying degrees (ADP: 9.1%, collagen: 17.7%, adrenalin: 28.6%, arachidonate: 1.0%), whereas aggregation induced by ristomycin (ristocetin) was close to normal level (52.2%, [Fig. 2B]), only slightly lower than the bottom of normal range (55.0–100.0%). In addition, tests for autoimmune antibodies were negative for common anti-platelet antibodies, including GPIX (CD42a), GPIB (CD42b), GPIIB (CD41), GPIIIA (CD61), and GMP140 (CD61p). Detailed laboratory results are summarized in [Table 1]. Assays Proband's results Reference interval Blood cell counts[a] Platelet count, ×10 9 /L 102.0 150.0–407.0 MPV, fL 12.9 9.0–13.8 PDW, fL 18.6 9.8–21.9 Thrombosis/hemostasis tests[b] PT, s 12.3 9.4–12.5 Prothrombin activity, % 97 80–130 INR 1.04 0.85–1.15 Fibrinogen, g/L 2.52 2.38–4.98 aPTT, s 37.0 25.1–36.5 TT, s 15.1 10.3–16.6 VWF assays[c] VWF:Ag (activity), % 111 50–200 VWF:Ag (level), % 105 50–200 VWF:Ag (activity)/VWF:Ag (level) ratio 1.06 Platelet aggregation[d] ADP (6 μM), % 9.1 50.0–100.0 Collagen (5 mg/L), % 17.7 55.0–100.0 Adrenalin (180 μM), % 28.6 55.0–100.0 Arachidonate (0.3 g/L), % 1.0 55.0–100.0 Ristomycin (1.5 g/L), % 52.2 55.0–100.0 Abbreviations: ADP, adenosine diphosphate; aPTT, activated partial thromboplastin time; INR, international normalized ratio; MPV, mean platelet volume; PDW, platelet distribution width; PT, prothrombin time; TT, thrombin time; VWF, von Willebrand factor. a The analysis of blood routine test was accomplished on Mindray CAL8000 hematology system. b The coagulation indicators PT, aPTT, TT, and fibrinogen were determined by coagulation assays using corresponding STA reagents (Diagnostica Stago, France) on a STA MAX automatic coagulation analyzer (Diagnostica Stago, France) according to the manufacturer's instructions. The indicators prothrombin activity and INR were calculated based on the result of PT. c The VWF antigen activity and level were detected by immunoturbidimetric assay using HemosIL VWF activity or antigen kits on ACL TOP 700 automatic coagulation analyzer (Instrumentation Laboratory, United States). d The platelet aggregation tests were conducted by optical turbidimetric assay using Helena platelet aggregation -Abstract Truncated-
peripheral vascular disease,hematology